GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program.
葛兰素史克公司（纽约证券交易所代码：GSK）周三搁置了其单纯疱疹病毒（HSV）疫苗开发计划。
The recombinant protein vaccine, dubbed GSK3943104, did not meet the study's primary efficacy objective.
这种名为 GSK3943104 的重组蛋白疫苗未达到该研究的主要疗效目标。
GSK added that the vaccine candidate will not progress to phase three studies.
GsK补充说，候选疫苗不会进入第三阶段的研究。
No safety concern was observed. The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up.
未观察到安全问题。TH HSV REC-003 研究将继续进行常规安全监测并进行后续跟进。
"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed," the company said. "GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV program."
该公司表示：“鉴于与生殖器疱疹相关的医疗需求和负担未得到满足，该领域仍需要创新。”“葛兰素史克打算评估所有这些数据和其他研究的总体情况，以推进其HSV计划的未来研发。”
There are no approved vaccines for HSV, and GSK's decision to stop developing GSK3943104 eliminates a key contender in the race to market.
目前尚无获批准的单纯疱疹病毒疫苗，葛兰素史克决定停止开发 GSK3943104，这使市场竞赛中的关键竞争者望而却步。
Moderna Inc (NASDAQ:MRNA) is developing mRNA-1608, an investigational vaccine for herpes simplex virus type 2. The candidate is currently in phase 1/2 trial that is fully enrolled with 300 participants in the U.S. Data is expected in June 2025.
摩德纳公司（纳斯达克股票代码：MRNA）正在开发mRNA-1608，这是一种针对2型单纯疱疹病毒的研究性疫苗。该候选人目前正在进行1/2期试验，该试验已全部入组，美国有300名参与者。数据预计将于2025年6月公布。
Pfizer Inc. (NYSE:PFE) partner BioNTech SE (NASDAQ:BNTX) is developing BNT163, a prophylactic vaccine candidate being studied in a phase one clinical trial.
辉瑞公司（纽约证券交易所代码：PFE）合作伙伴BioNTech SE（纳斯达克股票代码：BNTX）正在开发 BNT163，这是一种正在第一阶段临床试验中研究的预防性候选疫苗。
The German company initiated the phase one trial in December 2022, with an estimated enrollment of 248 participants. Data is expected in 2025.
这家德国公司于2022年12月启动了第一阶段试验，估计注册了248名参与者。数据预计将在2025年公布。
There are an estimated four billion people globally infected with HSV.
据估计，全球有40亿人感染了单纯疱疹病毒。
GSK Price Action: GSK stock is down 1.12% at $43.61 at last check Wednesday.
葛兰素史克价格走势：在周三的最后一次检查中，葛兰素史克股价下跌1.12％，至43.61美元。
- Rocket Lab USA Hires Rivian Veteran Frank Klein As New COO – What's Going On?
- 美国火箭实验室聘请 Rivian 资深人士弗兰克·克莱因担任新任首席运营官——发生了什么？